Michael Paltiel, MD
Dermatology · Forest Hills, NYNPI 1760525935
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 623 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations.
Across 623 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$1K
- Lilly USA, LLC$1K
- Sanofi$993
- Sun Pharmaceutical Industries Inc.$963
- Johnson & Johnson$920
- plus $6K from 26 others
Across 4 payments — averaging $2302.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$9K
What the payments were for
- Food & beverage$13,18699%
- Education$1641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 114 | $2,222 |
| Pfizer | 53 | $1,030 |
| Lilly USA, LLC | 45 | $1,020 |
| Sanofi | 37 | $993 |
| Sun Pharmaceutical Industries Inc. | 59 | $963 |
| Johnson & Johnson | 43 | $920 |
| Merz North America, Inc. | 6 | $779 |
| Amgen | 21 | $536 |
| Arcutis Biotherapeutics, Inc. | 31 | $533 |
| Novartis | 27 | $471 |
| Regeneron Healthcare Solutions, Inc. | 18 | $448 |
| Dermavant Sciences, Inc. | 17 | $436 |
| VYNE Pharmaceuticals Inc. | 14 | $353 |
| Mayne Pharma Commercial LLC | 19 | $342 |
| Incyte Corporation | 16 | $341 |
| E.r. Squibb & Sons, L.L.C. | 20 | $316 |
| Galderma Laboratories, L.p. | 17 | $300 |
| Organon | 10 | $205 |
| Bristol Myers Squibb | 11 | $183 |
| UCB, Inc. | 9 | $164 |
| LEO Pharma Inc. | 7 | $153 |
| Verrica Pharmaceuticals Inc. | 6 | $144 |
| Prugen, Inc. Pharmaceuticals | 5 | $138 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $99 |
| Dermira, Inc. | 5 | $85 |
| Botanix SB Inc | 2 | $56 |
| Cipher Pharmaceuticals US LLC | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| LNHC, Inc | 1 | $23 |
| EPI Health, LLC | 1 | $21 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Mission Pharmacal Company | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$736
How this compares
$13,350 in reported general payments places this provider in the 80th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 23 | $110,454 |
| OpzeluraRuxolitinib Phosphate | 30 | $59,385 |
| JubliaEfinaconazole | 25 | $33,490 |
| Ketoconazole | 387 | $13,347 |
| ZoryveRoflumilast | 14 | $11,705 |
| Tacrolimus | 60 | $9,062 |
| Metronidazole | 193 | $8,746 |
| Triamcinolone Acetonide | 167 | $5,504 |
| Halobetasol Propionate | 88 | $3,836 |
| Clobetasol Propionate | 81 | $3,005 |
| Nystatin | 81 | $1,022 |
| Ammonium Lactate | 53 | $922 |
| Clindamycin Phosphate | 24 | $855 |
| ValacyclovirValacyclovir Hcl | 58 | $808 |
| Hydrocortisone | 78 | $798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $536 | $110,45423 claims |
| Incyte CorporationOpzelura | $341 | $59,38530 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $99 | $33,49025 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $533 | $11,70514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,151 dermatology providers in New York.
Other dermatology in Forest Hills
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
- Emma GuttmanNew York$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.